Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.55 |
| ▸ | ALKBH3 | Q96Q83 | 12/20 | 0.42 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MT-CO1 | P00395 | 1/20 | 0.40 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15642918 | 0.79 | KDM4E (0.49) | KDM4EALKBH3KAT8 | |
| SCHEMBL15258879 | 0.78 | KDM4E (0.51) | KDM4EPOLBMAPTTDP1L3MBTL1 | |
| SCHEMBL15258736 | 0.78 | KDM4E (0.53) | KDM4EALKBH3KAT8POLBMAPT | |
| Hydrochloric Acid SCHEMBL15258719 | 0.78 | KDM4E (0.48) | KDM4EALKBH3KAT8 | |
| SCHEMBL15258785 | 0.78 | KDM4E (0.58) | KDM4EALKBH3KAT8POLBMAPT | |
| SCHEMBL3112565 | 0.77 | KDM4E (0.55) | KDM4EALKBH3KAT8POLBMAPT | |
| SCHEMBL2565000 | 0.77 | KDM4E (0.57) | KDM4EALKBH3KAT8POLBMAPT | |
| SCHEMBL15258816 | 0.76 | KDM4E (0.56) | KDM4EALKBH3KAT8POLBMAPT | |
| SCHEMBL2568176 | 0.76 | KDM4E (0.55) | KDM4EALKBH3KAT8POLBMAPT | |
| SCHEMBL3113813 | 0.75 | KDM4E (0.53) | KDM4EALKBH3KAT8POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102333769-B | Derivatives of 2-pyridin-2-yl-pyrazol-3 (2H) -one, preparation thereof, and therapeutic use as HIF activators | SANOFI AVENTIS | 2014-08-27 | — | — | CN | claimed |
| EP-2382205-B1 | DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF AS HIF ACTIVATORS | SANOFI SA (FR) | 2014-04-23 | — | — | EP | claimed |
| US-8541455-B2 | Derivatives of 2-pyridin-2-yl-pyrazol-3(2H)-one, preparation and therapeutic use thereof as HIF activators | SANOFI (FR) | 2013-09-24 | — | — | US | claimed |
| CN-102333769-A | Derivatives of 2-pyridin-2-yl-pyrazol-3 (2H) -one, preparation thereof, and therapeutic use as HIF activators | SANOFI AVENTIS | 2012-01-25 | — | — | CN | claimed |
| US-20110294788-A1 | DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF AS HIF ACTIVATORS | SANOFI (FR) | 2011-12-01 | — | — | US | claimed |
| EP-2382205-A2 | DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF AS HIF ACTIVATORS | SANOFI (FR) | 2011-11-02 | — | — | EP | claimed |
| WO-2010076524-A2 | DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF AS HIF ACTIVATORS | SANOFI-AVENTIS (FR) | 2010-07-08 | — | — | WO | claimed |
| CN-102333769-B | Derivatives of 2-pyridin-2-yl-pyrazol-3 (2H) -one, preparation thereof, and therapeutic use as HIF activators | SANOFI AVENTIS | 2014-08-27 | — | — | CN | disclosed |
| EP-2382205-B1 | DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF AS HIF ACTIVATORS | SANOFI SA (FR) | 2014-04-23 | — | — | EP | disclosed |
| US-8541455-B2 | Derivatives of 2-pyridin-2-yl-pyrazol-3(2H)-one, preparation and therapeutic use thereof as HIF activators | SANOFI (FR) | 2013-09-24 | — | — | US | disclosed |
| CN-102333769-A | Derivatives of 2-pyridin-2-yl-pyrazol-3 (2H) -one, preparation thereof, and therapeutic use as HIF activators | SANOFI AVENTIS | 2012-01-25 | — | — | CN | disclosed |
| US-20110294788-A1 | DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF AS HIF ACTIVATORS | SANOFI (FR) | 2011-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294788-A1 | DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF AS HIF ACTIVATORS | HIF1AN, HIF1A, EGLN2 | KDM4E 1006/4885ALKBH3 2359/4885KAT8 1503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.